Headlands Technologies LLC Has $3.30 Million Stock Position in Boston Scientific Corporation $BSX

Headlands Technologies LLC grew its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 239.9% in the 2nd quarter, Holdings Channel.com reports. The fund owned 77,266 shares of the medical equipment provider’s stock after purchasing an additional 54,534 shares during the period. Headlands Technologies LLC’s holdings in Boston Scientific were worth $3,298,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of BSX. Senator Investment Group LP acquired a new stake in Boston Scientific in the second quarter valued at $12,804,000. Quantitative Investment Management LLC lifted its holdings in Boston Scientific by 128.1% during the 2nd quarter. Quantitative Investment Management LLC now owns 213,737 shares of the medical equipment provider’s stock worth $9,122,000 after buying an additional 120,019 shares during the period. Moore Capital Management LP bought a new stake in shares of Boston Scientific in the 2nd quarter valued at about $8,077,000. Sigma Planning Corp increased its stake in shares of Boston Scientific by 15.9% in the second quarter. Sigma Planning Corp now owns 8,759 shares of the medical equipment provider’s stock valued at $374,000 after buying an additional 1,199 shares during the period. Finally, Two Sigma Securities LLC raised its position in shares of Boston Scientific by 261.3% during the second quarter. Two Sigma Securities LLC now owns 98,200 shares of the medical equipment provider’s stock worth $4,191,000 after acquiring an additional 71,019 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on BSX shares. Robert W. Baird set a $56.00 target price on Boston Scientific in a report on Thursday, July 30th. Jefferies Financial Group dropped their price target on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, June 24th. Wells Fargo & Company decreased their price objective on shares of Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating for the company in a research report on Thursday, July 30th. Weiss Ratings downgraded shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, July 7th. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $57.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $71.62.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney purchased 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward J. Ludwig acquired 5,000 shares of the company’s stock in a transaction dated Friday, July 31st. The shares were bought at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders purchased 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is currently owned by company insiders.

Boston Scientific Price Performance

Shares of BSX opened at $46.82 on Monday. The firm has a market cap of $67.85 billion, a PE ratio of 18.96, a price-to-earnings-growth ratio of 1.02 and a beta of 0.56. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The business’s 50 day moving average price is $46.56 and its two-hundred day moving average price is $56.53. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter last year, the firm posted $0.75 EPS. The company’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its board has approved a stock buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.